첫 페이지 美股新闻 본문
  每经AI快讯,11月28日消息,礼来宣布muvalaplin的2期临床研究取得积极结果。Muvalaplin是一种在研的用于降低脂蛋白(a)[Lp(a)]的每日一次口服药物。Lp(a)是一种遗传相关的且和心血管疾病有关的危险因素。研究表明,muvalaplin能显著降低成人Lp(a)水平,达到了主要终点[即从基线到第12周Lp(a)变化百分比]。
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

稀土掘金 注册会员
  • Follow

    0

  • Following

    0

  • Articles

    32